A. Witjes

发表

Safety and efficacy of the erdafitinib (erda) intravesical delivery system, TAR-210, in patients (pts) with non–muscle-invasive bladder cancer (NMIBC) or muscle-invasive bladder cancer (MIBC) harboring select FGFR mutations or fusions: Phase 1 first-in-human study.

Ó. Rodríguez Faba, R. Meijer, N. Shore, 2023, Journal of Clinical Oncology.

Longitudinal follow‐up and performance validation of an mRNA‐based urine test (Xpert® Bladder Cancer Monitor ) for surveillance in patients with non‐muscle‐invasive bladder cancer

Sanjay G. Patel, Y. Lotan, V. Reuter, 2021, BJU international.